M. Ebert et al., INCREASED MDM2 EXPRESSION AND IMMUNOREACTIVITY IN HUMAN PANCREATIC DUCTAL ADENOCARCINOMA, International journal of oncology, 5(6), 1994, pp. 1279-1284
The murine double minute-2 (MDM2) gene encodes a 90 kDa protein which
binds and inactivates the protein product of the p53 tumor suppressor
gene. To elucidate the potential role of MDM2 in benign and malignant
hyperproliferative conditions in the pancreas, we studied MDM2 express
ion in cultured human pancreatic cancer cells and in pancreatic tissue
s from normal donors, patients with pancreatic ductal adenocarcinoma a
nd patients with chronic pancreatitis (CP). All the tested cell lines
(PANC-1, COLO-357, HPAF and T3M4) expressed a 5.5 kilobase MDM2 mRNA t
ranscript and exhibited nuclear MDM2 immunostaining. MDM2 mRNA levels
were comparable in all 18 normal and 14 CP tissues for which RNA sampl
es were available for analysis. By comparison with the normal samples,
MDM2 mRNA levels were increased 6.4-fold in 8 of 12 human pancreatic
cancer samples (p < 0.0001). All 8 samples exhibited nuclear MDM2 immu
nostaining, which was also present in 24 of 37 additional pancreatic c
ancers. Mild MDM2 immunoreactivity was seen in only 1 of 20 CP samples
and in none of the 18 normal samples. These findings indicate that MD
M2 is overexpressed in a majority of pancreatic adenocarcinomas, but n
ot in CP samples. This selective overexpression raises the possibility
that MDM2 may contribute to pancreatic neoplastic transformation by i
nterfering with the growth-suppressing activity of wild-type p53.